A Clinical Randomized Control Trial of Combination TACE With and Without Low-Molecular-Weight Heparin in Hepatocellular Carcinoma

Inclusion Criteria:

1. Adults patients with a diagnosis of HCC which is not amenable to surgical resection,
liver transplantation or local ablative therapy

2. Without metastasis out of liver

3. Patients must have at least one tumor lesion that meets both of the following
criteria:

1. The lesion can be accurately measured in at least one dimension according to
RECIST criteria

2. The lesion has not been previously treated with surgery, radiation therapy,
radiofrequency ablation, percutaneous ethanol or acetic acid injection, or
cryoablation.

4. ECOG performance status (PS) <2

5. No prior targeted antiangiogenic therapy. Metronomic chemotherapies are allowed. At
least 4 weeks since prior systemic chemotherapy

6. Child-Pugh class A or B

7. No significant renal impairment (creatinine clearance < 30 mL/minute) or patients on
dialysis

8. Ability to understand the protocol and to agree to and sign a written informed
consent document -

Exclusion Criteria:

1. HBSAg(-)，AFP(-).

2. prothrombin time prolonged more than 4s.

3. blood platelets count less than 50000/L.

4. Renal failure requiring dialysis.

5. Child-Pugh class C hepatic impairment.

6. clinically significant gastrointestinal bleeding within 30 days prior to study entry.

7. History of organ allograft.

8. Substance abuse (current), psychological, or social conditions that may interfere
with the patient's participation in the study or evaluation of the study results.

9. Known or suspected allergy to the investigational agents or any agent given in
association with this trial.

10. Pregnant or breast-feeding patients.